Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-22
2006-08-22
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07094766
ABSTRACT:
Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, vitiligo, atopic dermatitis, or hyperproliferative or UV-responsive dermatoses, hyperproliferative or allergically mediated diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are disclosed.
REFERENCES:
patent: 3937809 (1976-02-01), Jacobi
patent: 4419343 (1983-12-01), Pauly
patent: 4508703 (1985-04-01), Redziniak et al.
patent: 4621023 (1986-11-01), Redziniak et al.
patent: 5077211 (1991-12-01), Yarosh
patent: 5455029 (1995-10-01), Hartman et al.
patent: 5470577 (1995-11-01), Gilchrest et al.
patent: 5532001 (1996-07-01), Gilchrest et al.
patent: 5580547 (1996-12-01), Gilchrest et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5599672 (1997-02-01), Liang et al.
patent: 5643556 (1997-07-01), Gilchrest et al.
patent: 5643890 (1997-07-01), Iversen et al.
patent: 5686306 (1997-11-01), West et al.
patent: 5858987 (1999-01-01), Beer-Romero et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 5955059 (1999-09-01), Gilchrest et al.
patent: 6007989 (1999-12-01), West et al.
patent: 6015710 (2000-01-01), Shay et al.
patent: 6020138 (2000-02-01), Akhavan-Tafti
patent: 6046307 (2000-04-01), Shay et al.
patent: 6103243 (2000-08-01), Russell-Jones et al.
patent: 6147056 (2000-11-01), Gilchrest et al.
patent: 6194206 (2001-02-01), West et al.
patent: 0 035 384 (1981-09-01), None
patent: 2 336 157 (1999-10-01), None
patent: WO 93/09788 (1993-05-01), None
patent: WO 93/22431 (1993-11-01), None
patent: WO 95/01773 (1995-01-01), None
patent: WO 95/07362 (1995-03-01), None
patent: WO 95/09175 (1995-04-01), None
patent: WO 97/08314 (1996-08-01), None
patent: WO 96/40989 (1996-12-01), None
patent: WO 97/44450 (1997-11-01), None
patent: WO 98/36066 (1998-02-01), None
patent: WO 99/03507 (1999-01-01), None
F Plenat, Molecular Medicine Today, “Animal models of antisense oligonucleotides: lessons for use in humans,” Jun. 1996, pp. 250-257.
PTC Ho et al.,Seminars in Oncology, “Antisense Oligonucleotides as Therapeutics for Malignant Diseases,” Apr. 1997, vol. 24, No. 2, pp. 187-202.
RA Stull et al., Pharmaceutical Research, “Antigene, Ribozyme and Aptamer Nucleic Acid Drugs:Progress and Prospects,” 1995, vol. 12, No. 4, pp. 465-483.
AD Branch, TIBS, “A good antisense molecule is hard to find,” 1998, vol. 23, pp. 45-50.
IM Verma et al., Nature, “Gene therapy-promises, problems and prospects,” Sep. 1997, vol. 389, pp. 239-242.
WF Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.
D Voet et al., Biochemistry, “DNA Replication, Repair and Recombination,” 1990, Chap.31, pp. 967-972.
DT Page et al., DDT, “Innovations in oral gene delivery:challenges and potentials,” Jan. 2001, vol. 6, No. 2, pp. 92-101.
T Ohnuma et al.,Anticancer Research, “Inhibitory Effects of Telomere-Mimic Phosphorothioate Oligonucleotides on Various Human Tumor Cells in Vitro,” 1997, 17, pp. 2455-2458.
TJ Page et al.,Experimental Cell Research, “The Cytotoxic Effects of Single-Stranded Telomere Mimics on OMA-BL1 Cells,” 1999, 252, pp. 41-49.
Gomez-Navarro et al. Gene Therapy for Cancer, European Journal of Cancer, vol. 35, pp. 867-885, 1999.
Niggli, H.J., et al., “Sunlight-Induced Pyrimidine Dimers In Human Skin Fibroblasts In Comparison With Dimerization After Artificial UV-Irradiation,”Photochemistry and Photobiology, 48(3):353-356 (1988).
Jayaraman, L., et al., “Activation of p53 Sequence-Specific DNA Binding by Short Single Strands of DNA Requires the p53 C-Terminus,”Cell, 81:1021-1029 (1995).
Kern S.E., et al., “Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression,”Science, 256:827-830 (1992).
Walworth, N.C., et al., “rad-Dependent Response of the chkl-Encoded Protein Kinase at the DNA Damage Checkpoint,”Science, 271:353-356 (1996).
El-Deiry, W.S., et al., “WAF1, a Potential Mediator of p53 Tumor Suppression,”Cell, 75:817-825 (1993).
Lu, X., et al., “Differential Induction of Transcriptionally Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?”Cell, 75:765-778 (1993).
Kastan, M.B., et al., “A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia,”Cell, 71:587-597 (1992).
Hupp, T.R., et al., “Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53,”Cell, 83:237-245 (1995).
Sanchez, Y., et al., “Regulation of RAD53 by the ATM-Like Kinases MEC1 and TEL1 in Yeast Cell Cycle Checkpoint Pathways,”Science, 271:357-360 (1996).
Fritsche, M., et al., “Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents,”Oncogene8:307-318 (1993).
Mitsudomi, T., et al., “p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features,”Oncogene7:171-180 (1992).
Nelson, W.G., et al., “DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways,”Mol. and Cell. Biol.14(3):1815-1823 (1994).
Wei, Q., et al., “DNA repair and aging in basal cell carcinoma: A molecular epidemiology study,”Proc. Natl. Acad. Sci. USA90:1614-1618 (1993).
Yaar, M., et al., “The trk Family of Receptors Mediates Nerve Growth Factor and Neurotrophin-3 Effects in Melanocytes,”J. Clin. Invest94:1550-1562 (1994).
Mitchell, D.L. and Karentz, D., “The Induction and Repair of DNA Photodamage in the Environment,” InEnvironment UV Photobiology, A.R. Young, et al., eds. (NY: Plenum Press), pp. 345-377 (1993).
Pedeux, R., et al., “Thymidine Dinucleotides Induce S Phase Cell Cycle Arrest in Addition to Increased Melanogenesis in Human Melanocytes,”Journal of Investigative Dermatology, 111:472-477 (1998).
Harley, C.B., et al., “Telomerase, Checkpoints and Cancer,” InCancer Surveys—Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology, Cold Spring Harbor Laboratory Press, 29:263-284 (1997).
Yaar, M., et al., “Aging Versus Photoaging: Postulated Mechanisms and Effectors,”The Society for Investigative Dermatology Symposium Proceedings, 3:47-51 (1998).
Parris, C.N., et al., “Telomerase activity in melanoma and non-melanoma skin cancer,”British Jour. of Cancer, 79(1):47-53 (1999).
Wu, K., et al., “Telomerase Activity and Telomere Length in Lymphocytes from Patients with Cutaneous T-Cell Lymphoma,”Cancer, 86(6):1056-1063 (1999).
Akiyama, M., et al, “Cytostatic Concentrations of Anticancer Agents do not Affect Telomerase Activity of Leukaemic CellsIn Vitro,” European Jour. of Cancer, 35(2):309-315 (1999).
Balasubramanian, S., et al., “Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse,”Oncogene, 18:1297-1302 (1999).
Wright, W.E. et al., “Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids,”The EMBO Journal, 15(7):1734-1741 (1996).
Mata, J. et al. “A Hexameric Phosporothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitts's Lymphoma Cellsin Vitroandin Vivo,” Toxicol. Appl. Pharmacol.144:189-197 (1997).
Eller, M.S. et al., “The Effect of Oligonucleotide Size and 5001′ Phosphate on Stimulation of Melanogenesis,”J. Invest. Dermatol.Abstract No. 113; vol. 112, No. 4, p. 541 (1999).
Eller Mark
Gilchrest Barbara A.
Yaar Mina
Clough David W.
Howrey LLP
Trustees of Boston University
Whiteman Brian
LandOfFree
Use of locally applied DNA fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of locally applied DNA fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of locally applied DNA fragments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3710099